Literature DB >> 18537970

Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?

Giselle Kidson-Gerber, Robert Lindeman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18537970     DOI： 10.1111/j.1365-2141.2008.07234.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

Authors:  Robert W Grady; Renzo Galanello; Rachel E Randolph; Dorothy A Kleinert; Carlo Dessi; Patricia J Giardina
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

2.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

Review 3.  Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

Authors:  Patricia M Fortin; Sheila A Fisher; Karen V Madgwick; Marialena Trivella; Sally Hopewell; Carolyn Doree; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.